These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2104 related articles for article (PubMed ID: 17697914)

  • 1. A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trial.
    Mathias SD; Bussel JB; George JN; McMillan R; Okano GJ; Nichol JL
    Clin Ther; 2007 May; 29(5):950-962. PubMed ID: 17697914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation.
    Mathias SD; Bussel JB; George JN; McMillan R; Okano GJ; Nichol JL
    Health Qual Life Outcomes; 2007 Feb; 5():11. PubMed ID: 17316442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials.
    George JN; Mathias SD; Go RS; Guo M; Henry DH; Lyons R; Redner RL; Rice L; Schipperus MR
    Br J Haematol; 2009 Feb; 144(3):409-15. PubMed ID: 19016720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care.
    Kuter DJ; Mathias SD; Rummel M; Mandanas R; Giagounidis AA; Wang X; Deuson RR
    Am J Hematol; 2012 May; 87(5):558-61. PubMed ID: 22460421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey.
    Snyder CF; Mathias SD; Cella D; Isitt JJ; Wu AW; Young J
    Curr Med Res Opin; 2008 Oct; 24(10):2767-76. PubMed ID: 18715526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences.
    Mathias SD; Gao SK; Rutstein M; Snyder CF; Wu AW; Cella D
    Curr Med Res Opin; 2009 Feb; 25(2):375-83. PubMed ID: 19192982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ITP-QoL questionnaire for children with immune thrombocytopenia: Italian version validation's.
    Giordano P; Lassandro G; Giona F; Jankovic M; Nardi M; Nobili B; Notarangelo LD; Russo G; Mackensen Sv
    Pediatr Hematol Oncol; 2014 Sep; 31(6):534-47. PubMed ID: 24852656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The reliability, validity, and preliminary responsiveness of the Eye Allergy Patient Impact Questionnaire (EAPIQ).
    Alexander M; Berger W; Buchholz P; Walt J; Burk C; Lee J; Arbuckle R; Abetz L
    Health Qual Life Outcomes; 2005 Oct; 3():67. PubMed ID: 16259630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
    Jamali F; Lemery S; Ayalew K; Robottom S; Robie-Suh K; Rieves D; Pazdur R
    Oncology (Williston Park); 2009 Jul; 23(8):704-9. PubMed ID: 19711585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura.
    Newland A; Caulier MT; Kappers-Klunne M; Schipperus MR; Lefrere F; Zwaginga JJ; Christal J; Chen CF; Nichol JL
    Br J Haematol; 2006 Nov; 135(4):547-53. PubMed ID: 17061981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.
    Kuter DJ; Bussel JB; Lyons RM; Pullarkat V; Gernsheimer TB; Senecal FM; Aledort LM; George JN; Kessler CM; Sanz MA; Liebman HA; Slovick FT; de Wolf JT; Bourgeois E; Guthrie TH; Newland A; Wasser JS; Hamburg SI; Grande C; Lefrère F; Lichtin AE; Tarantino MD; Terebelo HR; Viallard JF; Cuevas FJ; Go RS; Henry DH; Redner RL; Rice L; Schipperus MR; Guo DM; Nichol JL
    Lancet; 2008 Feb; 371(9610):395-403. PubMed ID: 18242413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.
    Bussel JB; Kuter DJ; George JN; McMillan R; Aledort LM; Conklin GT; Lichtin AE; Lyons RM; Nieva J; Wasser JS; Wiznitzer I; Kelly R; Chen CF; Nichol JL
    N Engl J Med; 2006 Oct; 355(16):1672-81. PubMed ID: 17050891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of utility values in the UK for health states related to immune thrombocytopenic purpura.
    Szende A; Brazier J; Schaefer C; Deuson R; Isitt JJ; Vyas P
    Curr Med Res Opin; 2010 Aug; 26(8):1893-903. PubMed ID: 20553121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
    Chouhan JD; Herrington JD
    Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP).
    Sanz MA; Aledort L; Mathias SD; Wang X; Isitt JJ
    Value Health; 2011 Jan; 14(1):90-6. PubMed ID: 21211490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of four self-report instruments (FABT, TSK-HC, Back-PAQ, HC-PAIRS) to measure healthcare practitioners' attitudes and beliefs toward low back pain: Reliability, convergent validity and survey of New Zealand osteopaths and manipulative physiotherapists.
    Moran RW; Rushworth WM; Mason J
    Musculoskelet Sci Pract; 2017 Dec; 32():44-50. PubMed ID: 28858681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life in children with chronic immune thrombocytopenia in China.
    Zhang H; Wang L; Quan M; Huang J; Wu P; Lu Q; Fang Y
    Health Qual Life Outcomes; 2016 Mar; 14():45. PubMed ID: 26979950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.
    Marquínez-Alonso I; Escudero-Vilaplana V; Pernía S; Beléndez Bieler C; Fernández-Llamazares CM; Sanjurjo-Sáez M
    J Clin Pharm Ther; 2014 Aug; 39(4):376-82. PubMed ID: 24702274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 106.